Epidemiology, outcomes, and the use of intensive care unit resources of critically ill patients diagnosed with COVID-19 in Sao Paulo, Brazil: A cohort study.
Adult
Aged
Aged, 80 and over
Brazil
/ epidemiology
COVID-19
/ epidemiology
Cohort Studies
Comorbidity
Critical Illness
Female
Humans
Intensive Care Units
/ statistics & numerical data
Length of Stay
/ statistics & numerical data
Male
Middle Aged
Mortality
/ trends
Respiration, Artificial
/ statistics & numerical data
Treatment Outcome
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
09
2020
accepted:
18
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
The coronavirus disease (COVID-19) pandemic has brought significant challenges worldwide, with high mortality, increased use of hospital resources, and the collapse of healthcare systems. We aimed to describe the clinical outcomes of critically ill COVID-19 patients and assess the impact on the use of hospital resources and compare with critically ill medical patients without COVID-19. In this retrospective cohort study, we included patients diagnosed with COVID-19 admitted to a private ICU in Sao Paulo, Brazil from March to June 2020. We compared these patients with those admitted to the unit in the same period of the previous year. A total of 212 consecutive patients with a confirmed diagnosis of COVID-19 were compared with 185 medical patients from the previous year. Patients with COVID-19 were more frequently males (76% vs. 56%, p<0.001) and morbidly obese (7.5% vs. 2.2%, p = 0.027), and had lower SAPS 3 (49.65 (12.19) vs. 55.63 (11.94), p<0.001) and SOFA scores (3.78 (3.53) vs. 4.48 (3.11), p = 0.039). COVID-19 patients had a longer ICU stay (median of 7 vs. 3 days, p<0.001), longer duration of mechanical ventilation (median of 9 vs. 4 days, p = 0.003), and more frequent tracheostomies (10.8 vs. 1.1%, p<0.001). Survival rates until 28 days were not statistically different (91% vs. 85.4%, p = 0.111). After multivariable adjustment for age, gender, SAPS 3, and Charlson Comorbidity Index, COVID-19 remained not associated with survival at 28 days (HR 0.59, 95% CI 0.33-1.06, p = 0.076). Among patients who underwent invasive mechanical ventilation, the observed mortality at 28-days was 16.2% in COVID-19 patients compared to 34.6% in the previous year. COVID-19 required more hospital resources, including invasive and non-invasive ventilation, had a longer duration of mechanical ventilation, and a more prolonged ICU and hospital length of stay. There was no difference in all-cause mortality at 28 and 60 days, suggesting that health systems preparedness be an important determinant of clinical outcomes.
Sections du résumé
BACKGROUND
The coronavirus disease (COVID-19) pandemic has brought significant challenges worldwide, with high mortality, increased use of hospital resources, and the collapse of healthcare systems. We aimed to describe the clinical outcomes of critically ill COVID-19 patients and assess the impact on the use of hospital resources and compare with critically ill medical patients without COVID-19.
METHODS AND FINDINGS
In this retrospective cohort study, we included patients diagnosed with COVID-19 admitted to a private ICU in Sao Paulo, Brazil from March to June 2020. We compared these patients with those admitted to the unit in the same period of the previous year. A total of 212 consecutive patients with a confirmed diagnosis of COVID-19 were compared with 185 medical patients from the previous year. Patients with COVID-19 were more frequently males (76% vs. 56%, p<0.001) and morbidly obese (7.5% vs. 2.2%, p = 0.027), and had lower SAPS 3 (49.65 (12.19) vs. 55.63 (11.94), p<0.001) and SOFA scores (3.78 (3.53) vs. 4.48 (3.11), p = 0.039). COVID-19 patients had a longer ICU stay (median of 7 vs. 3 days, p<0.001), longer duration of mechanical ventilation (median of 9 vs. 4 days, p = 0.003), and more frequent tracheostomies (10.8 vs. 1.1%, p<0.001). Survival rates until 28 days were not statistically different (91% vs. 85.4%, p = 0.111). After multivariable adjustment for age, gender, SAPS 3, and Charlson Comorbidity Index, COVID-19 remained not associated with survival at 28 days (HR 0.59, 95% CI 0.33-1.06, p = 0.076). Among patients who underwent invasive mechanical ventilation, the observed mortality at 28-days was 16.2% in COVID-19 patients compared to 34.6% in the previous year.
CONCLUSIONS
COVID-19 required more hospital resources, including invasive and non-invasive ventilation, had a longer duration of mechanical ventilation, and a more prolonged ICU and hospital length of stay. There was no difference in all-cause mortality at 28 and 60 days, suggesting that health systems preparedness be an important determinant of clinical outcomes.
Identifiants
pubmed: 33270741
doi: 10.1371/journal.pone.0243269
pii: PONE-D-20-28770
pmc: PMC7714136
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0243269Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Emerg Infect Dis. 2020 Aug;26(8):1679-1685
pubmed: 32407284
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Anaesthesia. 2020 Oct;75(10):1340-1349
pubmed: 32602561
Circulation. 2016 Jan 26;133(4):422-33
pubmed: 26811272
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
SN Compr Clin Med. 2020 Jun 25;:1-8
pubmed: 32838147
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1430-1434
pubmed: 32267160
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
CMAJ. 2020 Jun 29;192(26):E694-E701
pubmed: 32461326
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
Expert Rev Clin Immunol. 2020 May;16(5):465-470
pubmed: 32237901